| Literature DB >> 34618462 |
Gaoping Cui1, Ying Qing1, Minghui Li1, Liya Sun1, Juan Zhang1, Lei Feng2, Jing Li3, Tianlu Chen4, Jijun Wang5, Chunling Wan1.
Abstract
Schizophrenia is a complex and highly heterogeneous mental illness with a prodromal period called clinical high risk (CHR) for psychosis before onset. Metabolomics is greatly promising in analyzing the pathology of complex diseases and exploring diagnostic biomarkers. Therefore, we conducted salivary metabolomics analysis in 83 first-episode schizophrenia (FES) patients, 42 CHR individuals, and 78 healthy controls with ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. The mass spectrometry raw data have been deposited on the MetaboLights (ID: MTBLS3463). We found downregulated aromatic amino acid metabolism, disturbed glutamine and nucleotide metabolism, and upregulated tricarboxylic acid cycle in FES patients, which existed even in the CHR stage and became more intense with the onset of the schizophrenia. Moreover, differential metabolites can be considered as potential diagnostic biomarkers and indicate the severity of the different clinical stages of disease. Furthermore, three disordered pathways were closely related to peripheral indicators of inflammatory response, oxidative stress, blood-brain barrier damage, and salivary microbiota. These results indicate that the disorder of oral metabolism occurs earlier than the onset of schizophrenia and is concentrated and intensified with the onset of disease, which may originate from the dysbiotic salivary microbiota and cause the onset of schizophrenia through the peripheral inflammatory response and redox system, suggesting the importance of oral-brain connection in the pathogenesis of schizophrenia.Entities:
Keywords: aromatic amino acid metabolism; clinical high risk of psychosis; glutamine and nucleotide metabolism; metabolomics; schizophrenia; tricarboxylic acid cycle
Mesh:
Substances:
Year: 2021 PMID: 34618462 DOI: 10.1021/acs.jproteome.1c00504
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 4.466